De Carvalho Newton Sergio
Vaccine. 2008 Nov 25;26(50):6293-4. doi: 10.1016/j.vaccine.2008.09.001. Epub 2008 Sep 18.
Prophylactic VLP-based vaccines effectively prevent papillomavirus infections with a high level of antibodies and safety. An 18% increased efficacy against CIN 2+ lesions associated with HPVs 16/18 has been observed with the appliance of the HPV16/18 AS04 adjuvanted recombinant vaccine.
基于病毒样颗粒(VLP)的预防性疫苗能有效预防乳头瘤病毒感染,产生高水平抗体且安全性高。使用HPV16/18 AS04佐剂重组疫苗后,观察到针对与HPV16/18相关的2级及以上宫颈上皮内瘤变(CIN 2+)的疗效提高了18%。